Aiming to achieve net zero for its business sites as well as the overall supply chain by 2050, Samsung Biologics has established and is implementing a detailed roadmap. We are approaching the reduction of Scope 1 and 2 GHG emissions through three main strategies: reduce, replace, and purchase renewable energy. For reducing Scope 3 emissions, we provide tailored support for each supplier.

Samsung Biologics Carbon Footprint(2023)

Upstream

66.87% (500,265tCO2eq)

Purchased goods and services :55.61%

Capital goods : 7.21%

Others : 4.05%

- Fuel and energy-related activities: 0.92% - Upstream transportation and distribution: 2.52% - Waste generated in operations: 0.20% - Business travel: 0.14% - Employee commuting: 0.27%

Site

29.36% (219,698tCO2eq)

Direct emissions (Scope 1): 9.25%

69,262tCO2eq

Indirect emissions (Scope 2): 20.11%

150,436tCO2eq

Downstream

3.77% (28,214tCO2eq)

Downstream transportation and distribution: 0.78%

Processing of sold products: 2.99%

Disposal of sold products: 0.0002%

To contribute to global net zero and minimize risks while maximizing opportunities based on climate change risk and opportunity analysis results, Samsung Biologics established net-zero goals by referring to the Science-Based Targets Initiative (SBTi) methodology and are implementing detailed strategies and roadmaps.

To reach net zero by 2050 or earlier, we expect our partners to:

Set Net Zero targets

• · Set Net Zero targets aligned with the 1.5 °C pathway (2050 or earlier).
• · Join climate initiatives such as SBTi and verify the targets.

Assess & disclose GHG emissions

• · Calculate Scope 1, 2 and 3 emissions.
• · Improve the accuracy through Life Cycle Assessments.
• · Disclose emissions and the status of climate change response via CDP or other global platforms.

Participate in an annual survey

• · Participate in our survey to share annual emissions reduction performance.
• · Set standards for calculating the share of emissions related to Samsung Biologics (product-level LCA, etc.).

Evaluation

We will continue to monitor the status of the supply chain’s climate change response through an Annual Survey and provide consultation opportunities to fulfill requirements and improve response levels.

We also invite our suppliers to allow us to conduct assessments and evaluations to increase our supply chain transparency and actively encourage participation in identifying areas of improvement.

Benefits

Through our evaluation and assessment program, Samsung Biologics will offer more opportunities and benefits in new process development and supply chain selection to suppliers who actively engage in climate change response activities.

To fully integrate sustainability into our value chain, our suppliers’ participation is vital and will serve as an opportunity to further reinforce our connection with clients to build a healthier future for all.